1335138-89-0

Usage

Uses

Used in Pharmaceutical Industry:
(2S)-5-amino-2-[1-(trans-4-methylcyclohexyl)-1H-imidazol-4-yl]methylvaleric acid p-toluenesulfonate salt is used as a potential pharmaceutical agent for the development of new drugs. Its unique structure, which includes an imidazole ring and a cyclohexyl group, may offer novel therapeutic properties and mechanisms of action. Further research is required to explore its potential uses and effects in treating various medical conditions.
Used in Chemical Research:
In the field of chemical research, (2S)-5-amino-2-[1-(trans-4-methylcyclohexyl)-1H-imidazol-4-yl]methylvaleric acid p-toluenesulfonate salt serves as a valuable compound for studying its chemical properties and reactivity. Its complex structure provides opportunities for investigating new chemical reactions and synthesis pathways, which could lead to the discovery of additional compounds with potential applications in various industries.

Upstream product

• 104-15-4 toluene-4-sulfonic acid 
• 1335144-15-4 methyl 5-[(tert-butoxycarbonyl)amino]-2-{[1-(trans-4-methylcyclohexyl)-1H-imidazol-4-yl]methyl}valerate 
• 1335139-10-0 [1-(trans-4-methylcyclohexyl)-1H-imidazol-4-yl]methanol 
• 1335139-09-7 ethyl 1-(trans-4-methylcyclohexyl)-1H-imidazole-4-carboxylate 
• 2523-55-9 trans-4-methylcyclohexanamine 
• 1335139-08-6 1-(trans-4-methylcyclohexyl)-1H-imidazole-4-carbaldehyde 
• 1335139-06-4 5-[(tert-butoxycarbonyl)amino]-2-(methoxycarbonyl)valeric acid 
• 1335139-07-5 dimethyl 2-(3-((tert-butoxycarbonyl)amino)propyl)malonate 
• 1335138-62-9 (2S)-5-amino-2-{[1-(trans-4-methylcyclohexyl)-1H-imidazol-4-yl]methyl}valeric acid 
• 1335139-72-4 methyl (2S)-5-[(tert-butoxycarbonyl)amino]-2-{[1-(trans-4-methylcyclohexyl)-1H-imidazol-4-yl]methyl}valerate 

Relevant academic research and scientific papers

METHOD FOR PRODUCING OPTICALLY ACTIVE VALERIC ACID DERIVATIVE

A method for producing a compound (4), which comprises allowing a compound (1) to react with hydrogen gas in an inert solvent, in the presence of a specific chiral ligand and a ruthenium catalyst, or in the presence of an asymmetric transition metal complex catalyst previously generated from the chiral ligand and the ruthenium catalyst.

METHOD FOR PRODUCING OPTICALLY ACTIVE VALERIC ACID DERIVATIVE

A method for producing a compound (3), which comprises allowing a compound (1) to react with hydrogen gas in an inert solvent, in the presence of a specific chiral ligand and a ruthenium catalyst, or in the presence of an asymmetric transition metal complex catalyst previously generated from the chiral ligand and the ruthenium catalyst.

CYCLOALKYL-SUBSTITUTED IMIDAZOLE DERIVATIVE

A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein A represents a C3 to C12 cycloalkyl group which may be substituted by one to three selected from a fluoro group, a hydroxy group, a C1 to C6 alkyl group, etc; R1, R2, and R3 each independently represent a hydrogen atom, a fluoro group, or a C1 to C6 alkyl group; R4 represents a hydrogen atom or a prodrug group; and Y represents -CH2-CHR5-CH2-NHR6 (wherein R5 represents a hydrogen atom, a C1 to C6 alkyl group, or a C1 to C6 alkoxy group, and R6 represents a hydrogen atom or a prodrug group), or the like exhibits excellent TAFIa inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, and the like.